Viridian Therapeutics, Inc.\de
A biotechnology company developing new treatments for thyroid eye disease, a rare autoimmune condition that makes the tissues behind the eye swell and bulge. Its lead experimental medicine, veligrotug, is an antibody designed to block the protein driving that swelling. The company was formed under its current name in 2022, taking "Viridian" from the green pigment, a nod to fresh growth.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13GPassive | 5% | 5.69M | Aug 20, 2026 |
| Point72 Capital Advisors, Inc. | 13GPassive | 5% | 5.69M | Aug 20, 2026 |
| Steven A. Cohen | 13GPassive | 5% | 5.69M | Aug 20, 2026 |
| Paradigm BioCapital Advisors LP | 13G/APassive | 6.1% | 6.72M | Aug 14, 2026 |
| Paradigm BioCapital Advisors GP LLC | 13G/APassive | 6.1% | 6.72M | Aug 14, 2026 |
| Senai Asefaw, M.D. | 13G/APassive | 6.1% | 6.72M | Aug 14, 2026 |
| Kynam Capital Management, LP | 13G/APassive | 5.7% | 0 | Aug 14, 2026 |
| Kynam Capital Management GP, LLC | 13G/APassive | 5.7% | 0 | Aug 14, 2026 |
| Yue Tang | 13G/APassive | 5.7% | 0 | Aug 14, 2026 |
| Paradigm BioCapital International Fund Ltd. | 13G/APassive | 5.3% | 5.90M | Aug 14, 2026 |